What is Syn-ake?
Syn-ake (INCI: Dipeptide Diaminobutyroyl Benzylamide Diacetate) is a synthetic tripeptide developed by DSM Nutritional Products (formerly Pentapharm) as a cosmetic analogue of Waglerin-1. Waglerin-1 is a 22-amino-acid peptide isolated from the venom of the Temple Viper (Tropidolaemus wagleri) that produces reversible muscular paralysis by blocking nicotinic acetylcholine receptors (nAChR).
Syn-ake is a small, stable, synthetically manufactured tripeptide that mimics the receptor-binding portion of Waglerin-1, without the immunogenic and systemic risks of the natural venom peptide.
Important: Syn-ake is a cosmetic ingredient, not a pharmaceutical. The information on this page is offered for educational and cosmetic formulation reference purposes. It is not medical advice.
Proposed mechanism of action
Syn-ake competes with acetylcholine at the delta subunit of the nicotinic acetylcholine receptor (nAChR) at the neuromuscular junction. When acetylcholine cannot bind effectively, the signal for muscle fiber contraction is reduced. This produces a localized, reversible attenuation of muscle movement.
Key distinctions from botulinum toxin:
- Botulinum toxin cleaves SNARE proteins, permanently blocking vesicle fusion until new synaptic connections form (weeks to months duration).
- Syn-ake competes reversibly at the receptor. Effect duration follows topical residence time — typically hours, requiring consistent daily application.
The mechanism targets the receptor level (postsynaptic), while Argireline and Leuphasyl target presynaptic vesicle release. This makes Syn-ake mechanistically complementary to the Argireline/Leuphasyl stack.
What the research says
A 2012 study by Draganov et al. using contractility assays demonstrated statistically significant reduction in muscle fiber contraction in cell models treated with Syn-ake at cosmetically relevant concentrations. DSM’s clinical data reports ~52% reduction in wrinkle depth after 28 days at 4% concentration in a 30-subject split-face study.
Independent peer-reviewed clinical evidence with large populations is limited. The mechanism (nAChR competitive antagonism) is pharmacologically established, but the extent to which topically applied concentrations reach neuromuscular junctions in intact skin has not been independently validated.
Typical use in formulations
- Concentration range: 1–4% in finished formulation
- Optimal pH: 5.0–7.0
- Solubility: Water-soluble; supplied as aqueous solution (commercial Syn-ake from DSM is pre-dissolved at 2% active in water/glycerin)
- Target area: Dynamic expression lines, forehead, crow’s feet, perioral lines driven by repetitive muscle contraction
- Incompatibilities: No major documented incompatibilities. Standard stability precautions apply: avoid prolonged high-temperature exposure (above 40°C) during manufacturing.
- Synergies: Mechanistically stacks with Argireline (presynaptic SNARE inhibition), Leuphasyl (presynaptic opioid-receptor modulation), and SNAP-8 (SNARE inhibition). A four-component formula covers presynaptic vesicle release, presynaptic excitability, and postsynaptic receptor binding.
Cosmetic vs. pharmaceutical context
Syn-ake is positioned in the cosmetic market as a “venom-inspired” or “botox alternative” ingredient. These terms are permissible in marketing as they describe a mode of inspiration, not a therapeutic claim. However, claims like “paralyzes muscles” or “acts like botox” imply drug function and must be avoided in product labeling under both FDA and EU regulations.
Acceptable cosmetic claims: “helps reduce the appearance of expression lines” or “inspired by Temple Viper venom for smoother-looking skin.”
Reported protocol (research reference)
| Reported dose | Typically used at 1–4% concentration in topical formulations. Studies suggest 4% as an effective upper target in commercial serums. |
|---|---|
| FDA status | Not FDA approved |